New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy

PARSIPPANY, N.J. and INDIANAPOLIS, March 15, 2010 - A new analysis of the TRITON-TIMI 38 study evaluated response rates in patients with a common genetic variant in the ABCB1 gene. Patients enrolled in the TRITON-TIMI 38 study were treated with dual antiplatelet therapy with either Plavix(R) (clopidogrel) plus aspirin or Effient(R) (prasugrel) plus aspirin and managed [...]